financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Maintains Buy Opinion On Adss Of Anheuser-busch Inbev
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Maintains Buy Opinion On Adss Of Anheuser-busch Inbev
May 5, 2026 2:46 AM

05:30 AM EDT, 05/05/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Our 12-month target price for Anheuser-Busch InBev ( BUD ) is raised to USD94 (from USD92). This implies a 20.8x 2026 P/E, a premium to the industry forward average of 12.5x and its five-year historical average of 17.6x. Our relative valuation reflects ABI's improved financial position, both in terms of profitability and indebtedness, which should translate into meaningful profit. We like ABI for its industry-leading margins (LTM EBIT margin: 26.4% vs. peers' average: 17.4%), which is expected to gain further on improving volume outlook. We raise our 2026 EPADS estimate to USD4.50 (from USD4.41) and 2027's to USD5.08 (from USD4.95). We think that forex transactional headwinds will continue to be an issue moving forward, but will not deter ABI from sustaining its growth momentum given evidence of strong volume recovery and positive development across its strategic drivers. We remain confident in ABI's growth trajectory given its global portfolio strength and resilient market share across its key markets.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Maintains Sell Opinion On Shares Of Devon Energy Corporation
Research Alert: CFRA Maintains Sell Opinion On Shares Of Devon Energy Corporation
May 11, 2026
07:20 AM EDT, 05/11/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: Our 12-month target price of $42, raised $2, reflects relative valuation and our DCF models. On a relative basis, we apply a 4.5x multiple of enterprise value to projected 2027...
Research Alert: CFRA Lifts Opinion On Shares Of Nrg Energy, Inc. To Buy From Hold
Research Alert: CFRA Lifts Opinion On Shares Of Nrg Energy, Inc. To Buy From Hold
May 11, 2026
10:10 AM EDT, 05/11/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: Our 12-month target price is unchanged at $189, valuing shares at 19.2x our next-12-month EPS estimate of $9.86, slightly below IPP peers averaging 19.5x but significantly above NRG's highly volatile...
Research Alert: CFRA Maintains Hold Opinion On Shares Of Albemarle Corporation
Research Alert: CFRA Maintains Hold Opinion On Shares Of Albemarle Corporation
May 11, 2026
08:00 AM EDT, 05/11/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We increase our 12-month target price by $43 to $229, valuing ALB at 27.1x on our 2027 EPS estimate, a premium to ALB's normalized average fwd P/E during the last...
Research Alert: CFRA Keeps Hold Opinion On Shares Of Globus Medical Inc.
Research Alert: CFRA Keeps Hold Opinion On Shares Of Globus Medical Inc.
May 11, 2026
09:15 AM EDT, 05/11/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our target to $84 from $98, based on 16.9x our 2027 EPS estimate, below GMED's five-year average forward P/E multiple. We raise our 2026 EPS view to $4.72...
Copyright 2023-2026 - www.financetom.com All Rights Reserved